Cell and gene therapies
for rare diseases
IPO Jun 2018 (NASDAQ: AVRO)

Universal cell-based
cancer immunotherapy
IPO Mar 2018 (NASDAQ: UMRX)

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Discovering and developing
novel integrin antagonists for
serious fibrotic diseases

Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Translating natural
RNA editing into new
possibilities for patients

Discovering new medicines
for severe
neurodegenerative diseases

New class of
regulated cell and
gene therapies

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Targeting progranulin and
lysosomal biology to treat
neurodegenerative diseases

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Patient-directed oncology
therapies across immune and
cancer cell pathways

Bispecific antibodies
to improve the treatment
of serious diseases

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019

Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)

First-in-class
RNA therapies
for severe genetic diseases

Designing Synthetic Biotic
living medicines to treat disease
(NASDAQ: SYBX)

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Highly-potent, targeted, and
combinable immuno-oncology
therapeutics

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Preventing axonal degeneration
in patients with
neurological diseases

Breakthrough computer-aided
drug design
for transformative medicines

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Creating breakthrough
therapies for neurological
and psychiatric conditions

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Novel MetAP2 therapeutics to transform
complex metabolic disorders –
IPO June 2014 (NASDAQ: ZFGN)

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Re-dosable, titratable genetic
medicines with drug-like properties
for patients with genetic diseases

Applying new insights in
hepcidin biology to
treat hematologic diseases

Pioneering targeted
therapies for serious
muscle diseases

Novel therapeutics
targeting
diseases of aging

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007